Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 39

1.

Drug responses are conserved across patient-derived xenograft models of melanoma leading to identification of novel drug combination therapies.

Ice RJ, Chen M, Sidorov M, Le Ho T, Woo RWL, Rodriguez-Brotons A, Luu T, Jian D, Kim KB, Leong SP, Kim H, Kim A, Stone D, Nazarian A, Oh A, Tranah GJ, Nosrati M, de Semir D, Dar AA, Chang S, Desprez PY, Kashani-Sabet M, Soroceanu L, McAllister SD.

Br J Cancer. 2019 Dec 20. doi: 10.1038/s41416-019-0696-y. [Epub ahead of print]

PMID:
31857724
2.

Durable multitransgene expression in vivo using systemic, nonviral DNA delivery.

Handumrongkul C, Ye AL, Chmura SA, Soroceanu L, Mack M, Ice RJ, Thistle R, Myers M, Ursu SJ, Liu Y, Kashani-Sabet M, Heath TD, Liggitt D, Lewis DB, Debs R.

Sci Adv. 2019 Nov 27;5(11):eaax0217. doi: 10.1126/sciadv.aax0217. eCollection 2019 Nov.

3.

Tissues Harvested Using an Automated Surgical Approach Confirm Molecular Heterogeneity of Glioblastoma and Enhance Specimen's Translational Research Value.

Zusman E, Sidorov M, Ayala A, Chang J, Singer E, Chen M, Desprez PY, McAllister S, Salomonis N, Chetal K, Prasad G, Kang T, Mark J, Dickinson L, Soroceanu L.

Front Oncol. 2019 Oct 23;9:1119. doi: 10.3389/fonc.2019.01119. eCollection 2019.

4.

Novel tumor suppressor role of miRNA-876 in cholangiocarcinoma.

Ursu S, Majid S, Garger C, de Semir D, Bezrookove V, Desprez PY, McAllister S, Soroceanu L, Nosrati M, Yimam K, Hassoun A, Osorio R, Kashani-Sabet M, Dar AA.

Oncogenesis. 2019 Aug 13;8(8):42. doi: 10.1038/s41389-019-0153-z.

5.

Publisher Correction: Toxoplasma Modulates Signature Pathways of Human Epilepsy, Neurodegeneration & Cancer.

Ngô HM, Zhou Y, Lorenzi H, Wang K, Kim TK, Zhou Y, El Bissati K, Mui E, Fraczek L, Rajagopala SV, Roberts CW, Henriquez FL, Montpetit A, Blackwell JM, Jamieson SE, Wheeler K, Begeman IJ, Naranjo-Galvis C, Alliey-Rodriguez N, Davis RG, Soroceanu L, Cobbs C, Steindler DA, Boyer K, Noble AG, Swisher CN, Heydemann PT, Rabiah P, Withers S, Soteropoulos P, Hood L, McLeod R.

Sci Rep. 2019 May 28;9(1):8110. doi: 10.1038/s41598-019-44545-0.

6.

PHIP as a therapeutic target for driver-negative subtypes of melanoma, breast, and lung cancer.

de Semir D, Bezrookove V, Nosrati M, Dar AA, Wu C, Shen J, Rieken C, Venkatasubramanian M, Miller JR 3rd, Desprez PY, McAllister S, Soroceanu L, Debs RJ, Salomonis N, Schadendorf D, Cleaver JE, Kashani-Sabet M.

Proc Natl Acad Sci U S A. 2018 Jun 19;115(25):E5766-E5775. doi: 10.1073/pnas.1804779115. Epub 2018 Jun 4.

7.

Toxoplasma Modulates Signature Pathways of Human Epilepsy, Neurodegeneration & Cancer.

Ngô HM, Zhou Y, Lorenzi H, Wang K, Kim TK, Zhou Y, El Bissati K, Mui E, Fraczek L, Rajagopala SV, Roberts CW, Henriquez FL, Montpetit A, Blackwell JM, Jamieson SE, Wheeler K, Begeman IJ, Naranjo-Galvis C, Alliey-Rodriguez N, Davis RG, Soroceanu L, Cobbs C, Steindler DA, Boyer K, Noble AG, Swisher CN, Heydemann PT, Rabiah P, Withers S, Soteropoulos P, Hood L, McLeod R.

Sci Rep. 2017 Sep 13;7(1):11496. doi: 10.1038/s41598-017-10675-6. Erratum in: Sci Rep. 2019 May 28;9(1):8110.

8.

A Cell-Surface Membrane Protein Signature for Glioblastoma.

Ghosh D, Funk CC, Caballero J, Shah N, Rouleau K, Earls JC, Soroceanu L, Foltz G, Cobbs CS, Price ND, Hood L.

Cell Syst. 2017 May 24;4(5):516-529.e7. doi: 10.1016/j.cels.2017.03.004. Epub 2017 Mar 29.

9.

Selective Toxicity of a Highly Potent Camptothecin Analogue: A Pilot Study with Glioblastoma Multiforme Cells.

Yount G, Soroceanu L, Wang HJ, Singer E, Yount R, Luu T, Yang LX.

Anticancer Res. 2016 Nov;36(11):5845-5848.

PMID:
27793907
10.

Cytomegalovirus Immediate-Early Proteins Promote Stemness Properties in Glioblastoma.

Soroceanu L, Matlaf L, Khan S, Akhavan A, Singer E, Bezrookove V, Decker S, Ghanny S, Hadaczek P, Bengtsson H, Ohlfest J, Luciani-Torres MG, Harkins L, Perry A, Guo H, Soteropoulos P, Cobbs CS.

Cancer Res. 2015 Aug 1;75(15):3065-76. doi: 10.1158/0008-5472.CAN-14-3307.

11.

The Antitumor Activity of Plant-Derived Non-Psychoactive Cannabinoids.

McAllister SD, Soroceanu L, Desprez PY.

J Neuroimmune Pharmacol. 2015 Jun;10(2):255-67. doi: 10.1007/s11481-015-9608-y. Epub 2015 Apr 28. Review.

12.

The role of BPTF in melanoma progression and in response to BRAF-targeted therapy.

Dar AA, Nosrati M, Bezrookove V, de Semir D, Majid S, Thummala S, Sun V, Tong S, Leong SP, Minor D, Billings PR, Soroceanu L, Debs R, Miller JR 3rd, Sagebiel RW, Kashani-Sabet M.

J Natl Cancer Inst. 2015 Feb 23;107(5). pii: djv034. doi: 10.1093/jnci/djv034.

13.

Reactive oxygen species-mediated therapeutic response and resistance in glioblastoma.

Singer E, Judkins J, Salomonis N, Matlaf L, Soteropoulos P, McAllister S, Soroceanu L.

Cell Death Dis. 2015 Jan 15;6:e1601. doi: 10.1038/cddis.2014.566.

14.

Human cytomegalovirus gene expression in long-term infected glioma stem cells.

Fiallos E, Judkins J, Matlaf L, Prichard M, Dittmer D, Cobbs C, Soroceanu L.

PLoS One. 2014 Dec 30;9(12):e116178. doi: 10.1371/journal.pone.0116178. eCollection 2014.

15.

HCMV glycoprotein B is expressed in primary glioblastomas and enhances growth and invasiveness via PDGFR-alpha activation.

Cobbs C, Khan S, Matlaf L, McAllister S, Zider A, Yount G, Rahlin K, Harkins L, Bezrookove V, Singer E, Soroceanu L.

Oncotarget. 2014 Feb 28;5(4):1091-100.

16.

Cidofovir: a novel antitumor agent for glioblastoma.

Hadaczek P, Ozawa T, Soroceanu L, Yoshida Y, Matlaf L, Singer E, Fiallos E, James CD, Cobbs CS.

Clin Cancer Res. 2013 Dec 1;19(23):6473-83. doi: 10.1158/1078-0432.CCR-13-1121. Epub 2013 Oct 29.

17.

Cytomegalovirus pp71 protein is expressed in human glioblastoma and promotes pro-angiogenic signaling by activation of stem cell factor.

Matlaf LA, Harkins LE, Bezrookove V, Cobbs CS, Soroceanu L.

PLoS One. 2013 Jul 5;8(7):e68176. doi: 10.1371/journal.pone.0068176. Print 2013.

18.

Id-1 is a key transcriptional regulator of glioblastoma aggressiveness and a novel therapeutic target.

Soroceanu L, Murase R, Limbad C, Singer E, Allison J, Adrados I, Kawamura R, Pakdel A, Fukuyo Y, Nguyen D, Khan S, Arauz R, Yount GL, Moore DH, Desprez PY, McAllister SD.

Cancer Res. 2013 Mar 1;73(5):1559-69. doi: 10.1158/0008-5472.CAN-12-1943. Epub 2012 Dec 13.

19.

Loss of cell-surface laminin anchoring promotes tumor growth and is associated with poor clinical outcomes.

Akhavan A, Griffith OL, Soroceanu L, Leonoudakis D, Luciani-Torres MG, Daemen A, Gray JW, Muschler JL.

Cancer Res. 2012 May 15;72(10):2578-88. doi: 10.1158/0008-5472.CAN-11-3732.

20.

Consensus on the role of human cytomegalovirus in glioblastoma.

Dziurzynski K, Chang SM, Heimberger AB, Kalejta RF, McGregor Dallas SR, Smit M, Soroceanu L, Cobbs CS; HCMV and Gliomas Symposium.

Neuro Oncol. 2012 Mar;14(3):246-55. doi: 10.1093/neuonc/nor227. Epub 2012 Feb 8.

21.

Human cytomegalovirus US28 found in glioblastoma promotes an invasive and angiogenic phenotype.

Soroceanu L, Matlaf L, Bezrookove V, Harkins L, Martinez R, Greene M, Soteropoulos P, Cobbs CS.

Cancer Res. 2011 Nov 1;71(21):6643-53. doi: 10.1158/0008-5472.CAN-11-0744. Epub 2011 Sep 7.

22.

Is HCMV a tumor promoter?

Soroceanu L, Cobbs CS.

Virus Res. 2011 May;157(2):193-203. doi: 10.1016/j.virusres.2010.10.026. Epub 2010 Oct 29. Review.

23.

Detection of human cytomegalovirus in normal and neoplastic breast epithelium.

Harkins LE, Matlaf LA, Soroceanu L, Klemm K, Britt WJ, Wang W, Bland KI, Cobbs CS.

Herpesviridae. 2010 Dec 23;1(1):8. doi: 10.1186/2042-4280-1-8.

24.

Platelet-derived growth factor-alpha receptor activation is required for human cytomegalovirus infection.

Soroceanu L, Akhavan A, Cobbs CS.

Nature. 2008 Sep 18;455(7211):391-5. doi: 10.1038/nature07209. Epub 2008 Aug 13.

PMID:
18701889
25.

Modulation of oncogenic phenotype in human glioma cells by cytomegalovirus IE1-mediated mitogenicity.

Cobbs CS, Soroceanu L, Denham S, Zhang W, Kraus MH.

Cancer Res. 2008 Feb 1;68(3):724-30. doi: 10.1158/0008-5472.CAN-07-2291.

26.

Human cytomegalovirus induces cellular tyrosine kinase signaling and promotes glioma cell invasiveness.

Cobbs CS, Soroceanu L, Denham S, Zhang W, Britt WJ, Pieper R, Kraus MH.

J Neurooncol. 2007 Dec;85(3):271-80. Epub 2007 Jun 23.

PMID:
17589804
27.

Identification of IGF2 signaling through phosphoinositide-3-kinase regulatory subunit 3 as a growth-promoting axis in glioblastoma.

Soroceanu L, Kharbanda S, Chen R, Soriano RH, Aldape K, Misra A, Zha J, Forrest WF, Nigro JM, Modrusan Z, Feuerstein BG, Phillips HS.

Proc Natl Acad Sci U S A. 2007 Feb 27;104(9):3466-71. Epub 2007 Feb 20.

28.

Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis.

Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano RH, Wu TD, Misra A, Nigro JM, Colman H, Soroceanu L, Williams PM, Modrusan Z, Feuerstein BG, Aldape K.

Cancer Cell. 2006 Mar;9(3):157-73.

30.

Reduced expression of connexin-43 and functional gap junction coupling in human gliomas.

Soroceanu L, Manning TJ Jr, Sontheimer H.

Glia. 2001 Feb;33(2):107-17.

PMID:
11180508
31.

Modulation of glioma cell migration and invasion using Cl(-) and K(+) ion channel blockers.

Soroceanu L, Manning TJ Jr, Sontheimer H.

J Neurosci. 1999 Jul 15;19(14):5942-54.

32.

Glioma migration can be blocked by nontoxic inhibitors of myosin II.

Gillespie GY, Soroceanu L, Manning TJ Jr, Gladson CL, Rosenfeld SS.

Cancer Res. 1999 May 1;59(9):2076-82.

33.

Use of chlorotoxin for targeting of primary brain tumors.

Soroceanu L, Gillespie Y, Khazaeli MB, Sontheimer H.

Cancer Res. 1998 Nov 1;58(21):4871-9.

34.

Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate.

Goldman CK, Kendall RL, Cabrera G, Soroceanu L, Heike Y, Gillespie GY, Siegal GP, Mao X, Bett AJ, Huckle WR, Thomas KA, Curiel DT.

Proc Natl Acad Sci U S A. 1998 Jul 21;95(15):8795-800.

35.

In vitro and in vivo gene delivery mediated by a synthetic polycationic amino polymer.

Goldman CK, Soroceanu L, Smith N, Gillespie GY, Shaw W, Burgess S, Bilbao G, Curiel DT.

Nat Biotechnol. 1997 May;15(5):462-6.

PMID:
9131627
36.

Evaluation of genetically engineered herpes simplex viruses as oncolytic agents for human malignant brain tumors.

Andreansky S, Soroceanu L, Flotte ER, Chou J, Markert JM, Gillespie GY, Roizman B, Whitley RJ.

Cancer Res. 1997 Apr 15;57(8):1502-9.

37.

The application of genetically engineered herpes simplex viruses to the treatment of experimental brain tumors.

Andreansky SS, He B, Gillespie GY, Soroceanu L, Markert J, Chou J, Roizman B, Whitley RJ.

Proc Natl Acad Sci U S A. 1996 Oct 15;93(21):11313-8. Review.

38.

Loss of vascular endothelial growth factor in human alopecia hair follicles.

Goldman CK, Tsai JC, Soroceanu L, Gillespie GY.

J Invest Dermatol. 1995 May;104(5 Suppl):18S-20S. No abstract available.

39.

Comparison of genetically engineered herpes simplex viruses for the treatment of brain tumors in a scid mouse model of human malignant glioma.

Chambers R, Gillespie GY, Soroceanu L, Andreansky S, Chatterjee S, Chou J, Roizman B, Whitley RJ.

Proc Natl Acad Sci U S A. 1995 Feb 28;92(5):1411-5.

Supplemental Content

Loading ...
Support Center